Trifecta Capital Advisors LLC Purchases 10,250 Shares of GRAIL, Inc. $GRAL

Trifecta Capital Advisors LLC lifted its position in shares of GRAIL, Inc. (NASDAQ:GRAL) by 89.9% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 21,650 shares of the company’s stock after purchasing an additional 10,250 shares during the period. Trifecta Capital Advisors LLC owned 0.06% of GRAIL worth $1,280,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Farther Finance Advisors LLC boosted its stake in shares of GRAIL by 768.1% in the 2nd quarter. Farther Finance Advisors LLC now owns 816 shares of the company’s stock worth $42,000 after buying an additional 722 shares during the last quarter. Roble Belko & Company Inc bought a new stake in GRAIL during the second quarter worth $68,000. Cypress Capital Management LLC WY bought a new stake in GRAIL during the second quarter worth $72,000. NewEdge Advisors LLC boosted its position in GRAIL by 390.3% in the first quarter. NewEdge Advisors LLC now owns 1,760 shares of the company’s stock worth $45,000 after purchasing an additional 1,401 shares during the last quarter. Finally, EverSource Wealth Advisors LLC grew its stake in GRAIL by 278.8% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,288 shares of the company’s stock valued at $118,000 after purchasing an additional 1,684 shares during the period.

Analysts Set New Price Targets

A number of equities research analysts recently commented on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of GRAIL in a report on Thursday, January 22nd. Morgan Stanley boosted their target price on GRAIL from $85.00 to $110.00 and gave the company an “equal weight” rating in a research note on Monday, December 1st. Canaccord Genuity Group increased their price target on GRAIL from $85.00 to $105.00 and gave the stock a “buy” rating in a research note on Monday, November 17th. Guggenheim boosted their price objective on GRAIL from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Monday. Finally, UBS Group set a $75.00 price objective on shares of GRAIL in a report on Friday, October 3rd. Two analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, GRAIL currently has a consensus rating of “Hold” and a consensus target price of $105.00.

GRAIL Trading Down 0.0%

Shares of NASDAQ:GRAL opened at $100.98 on Friday. The company has a 50 day moving average of $98.12 and a 200 day moving average of $69.25. The stock has a market cap of $3.94 billion, a P/E ratio of -8.68 and a beta of 4.52. GRAIL, Inc. has a 12 month low of $20.44 and a 12 month high of $118.84.

GRAIL (NASDAQ:GRAL) last posted its earnings results on Wednesday, November 12th. The company reported ($2.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($3.40) by $0.94. The business had revenue of $36.19 million for the quarter, compared to analysts’ expectations of $33.83 million. GRAIL had a negative net margin of 286.43% and a negative return on equity of 15.69%. On average, equities analysts forecast that GRAIL, Inc. will post -15.15 earnings per share for the current fiscal year.

About GRAIL

GRAIL, Inc (NASDAQ: GRAL) is a biotechnology company dedicated to the early detection of cancer through a multi-cancer blood test. Leveraging advances in next-generation sequencing, cell-free DNA (cfDNA) analysis and machine learning, GRAIL has developed the Galleri™ test, which aims to identify more than 50 types of cancer at their earliest stages. The company’s platform analyzes methylation patterns in circulating tumor DNA to pinpoint tumor presence and tissue of origin, enabling physicians to pursue timely diagnostic follow-up.

Founded in 2016 as a spin-out from Illumina, GRAIL established its headquarters in Menlo Park, California, with additional research and operations centers in the United Kingdom.